FLINT, Mich. – May 18, 2017 – The nation’s largest independent specialty pharmacy is now dispensing RYDAPT® (midostaurin) to treat adults who have FLT3 mutation–positive acute myeloid leukemia.

Diplomat Pharmacy, Inc. (NYSE: DPLO), is now dispensing RYDAPT® (midostaurin), recently approved by the Food and Drug Administration.

RYDAPT® (midostaurin) is approved to treat newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation–positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.

RYDAPT® (midostaurin) inhibits multiple receptor tyrosine kinases.

An oral therapy, RYDAPT® (midostaurin) is administered twice daily for adults with FLT3 mutation–positive AML.

The FDA also approved RYDAPT® (midostaurin) to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia. RYDAPT® (midostaurin) is not indicated as a single-agent induction therapy for patients with AML.

To learn more about Diplomat’s oncology program, visit diplomat.is/areas-of-excellence/oncology.

“We are excited about the recent approval of RYDAPT® (midostaurin) to treat newly diagnosed FLT3-mutated AML patients. It opens a new treatment strategy for these patients,” said Paul Urick, Diplomat president. “We understand cancer treatments can be complex. Through our coordinated care team, we are eager to provide patients this encouraging new therapy option with our expertise and personal support.”

According to the American Cancer Society, AML is a form of cancer in which the bone marrow makes irregular myeloblasts, red blood cells, or platelets. Symptoms can include fatigue, recurrent infections, and easy bruising. AML is most common in people older than 45.

RYDAPT® (midostaurin) is manufactured by Novartis Pharmaceutical Corporation. For full prescribing information, click here.


Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.


Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is